An international medical devices company that manufactures, engineers and markets products for infection management, Biocomposites, has been awarded two Queen’s Awards for Enterprise for Innovation and International Trade. This makes Biocomposites one of seven organisations nationally to achieve two Queen’s Awards in 2022.
The creation of STIMULAN Rapid Cure, a calcium sulphate antibiotic carrier licenced for use in infected bone and soft tissue, has earned Biocomposites an award in the Innovation category.
“Biocomposites have been awarded two Queen’s Awards for Enterprise for Innovation and International Trade.“
In the International Trade category, the company was also recognised for its increased foreign sales. Sales of its products in 40 countries, including the United States, the Netherlands, China, Canada, and India, have increased by more than 200 per cent in the last six years.
Chief Executive Officer, Biocomposites, Michael Harris, stated: “The Queen’s Awards are the most prestigious business awards in the UK and we are proud that Biocomposites has been honoured with two of them. It is very pleasing to see our relentless focus on research and development recognised with an innovation award for STIMULAN as well as recognition for our incredible growth in global markets. I would like to thank the entire team at Biocomposites whose dedication to innovation and helping patients has made this achievement possible.”